There are currently 413 clinical trials in Grand Rapids, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Spectrum Health - Butterworth Campus, Trinity Health Grand Rapids Hospital and CCOP - Grand Rapids. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
NCT06270082
Recruiting
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue, administered orally as monotherapy in patients with advanced solid tumors with gene alterations in the RAS- MAPK pathway for whom there are no further treatment options known to confer clinical benefit.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
Register for Updates
Citadel Embolization Device Study
NCT04057352
Recruiting
The purpose of this study is to gather safety and effectiveness data on Stryker Neurovascular's Next Generation Target Detachable Coil (hereafter referred to as the Citadel Embolization Device), when used with Target Detachable Coils, in the treatment of wide-neck intracranial aneurysms.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/24/2025
Locations: Spectrum Health, Grand Rapids, Michigan
Conditions: Unruptured Wide-neck Aneurysms
Register for Updates
Evaluate REC-4881 in Patients With FAP
NCT05552755
Recruiting
This is a multicenter, two-part trial in participants with Familial Adenomatous Polyposis (FAP).
Gender:
ALL
Ages:
55 years and above
Trial Updated:
04/24/2025
Locations: Corewell Health (Spectrum Health Hospitals Colorectal Cancer Multis), Grand Rapids, Michigan
Conditions: Familial Adenomatous Polyposis
Register for Updates
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)
NCT04546126
Recruiting
This study will evaluate the feasibility of using a sub-therapeutic dose of a fluorine-18 analogue of NP-59 (\[18F\]FNP-59) to image the adrenal gland. Some participants are healthy normal subjects but have undergone interventions to manipulate hormones while other participants have known adrenal pathology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: BAMF Health, Inc., Grand Rapids, Michigan
Conditions: Radiotracer, Hypertension, Cholesterol
Register for Updates
FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06402331
Recruiting
This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). Patient population is adult participants with PSMA positive mCRPC who have had previous treatment with with 177Lu-PSMA-617 or another 177Lu-PSMA radioconjugate (RC). The purpose of the study is to determine the safety and tolerability, and recommended dose and regiment of FPI-2265.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: BAMF Health, Grand Rapids, Michigan
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
Conditioning SCID Infants Diagnosed Early
NCT03619551
Recruiting
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related dono... Read More
Gender:
ALL
Ages:
Between 0 years and 2 years
Trial Updated:
04/22/2025
Locations: Helen DeVos Children's, Grand Rapids, Michigan
Conditions: SCID
Register for Updates
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT06400472
Recruiting
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: South Texas Accelerated Research Therapeutics (START), Grand Rapids, Michigan
Conditions: Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
Register for Updates
Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
NCT06932081
Recruiting
This real-world, international registry aims to evaluate the current experience with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in adult congenital heart disease (ACHD) patients by investigating the prescription patterns, safety, tolerability, and potential beneficial effects on heart failure-related outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Adult Congenital Heart Disease, Congenital Heart Disease, Systemic Right Ventricle, Transposition of the Great Arteries, Congenitally Corrected Transposition of the Great Arteries, Fontan, Single Ventricle, Tetralogy of Fallot (TOF)
Register for Updates
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069
Recruiting
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids, Michigan
Conditions: Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer
Register for Updates
AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion
NCT06029660
Recruiting
To determine the safety and effectiveness of IMPEDE-FX RapidFill to increase the percentage of subjects with shrinkage of the abdominal aortic aneurysm sac when used as an adjunct to on-label endovascular aneurysm repair (EVAR) stent graft treatment in trial subjects considered candidates for elective EVAR.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Aortic Aneurysm, Abdominal
Register for Updates
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
NCT01351545
Recruiting
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Gender:
ALL
Ages:
All
Trial Updated:
04/15/2025
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan +1 locations
Conditions: Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Severe Aplastic Anemia, Autoimmune Diseases
Register for Updates
Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
NCT04523727
Recruiting
This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
Gender:
ALL
Ages:
Between 6 years and 16 years
Trial Updated:
04/15/2025
Locations: Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan
Conditions: Hyperphosphatemia Related to Chronic Kidney Disease
Register for Updates